Double-Blind, Placebo-Controlled Study of the Therapeutic Use of Recombinant Human Erythropoietin for Anemia Associated With Chronic Renal Failure in Predialysis Patients
- 1 July 1991
- journal article
- clinical trial
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 18 (1) , 50-59
- https://doi.org/10.1016/s0272-6386(12)80290-3
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Treatment of the Anemia of Progressive Renal Failure with Recombinant Human ErythropoietinNew England Journal of Medicine, 1989
- Treatment of the Anemia of Predialysis Patients with Recombinant Human Erythropoietin: A Randomized, Placebo-Controlled TrialThe Lancet Healthy Longevity, 1988
- Serum Creatinine and Renal FunctionAnnual Review of Medicine, 1988
- Therapie der renalen Anämie mit rekombinantem humanem ErythropoietinDeutsche Medizinische Wochenschrift (1946), 1988
- Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis.BMJ, 1987
- Erythropoietin–hematocrit feedback circuit in the anemia of end–stage renal diseaseKidney International, 1987
- Correction of the Anemia of End-Stage Renal Disease with Recombinant Human ErythropoietinNew England Journal of Medicine, 1987
- ERYTHROPOIETIN TREATMENT IN ANAEMIC PATIENTS ON HAEMODIALYSISThe Lancet, 1986
- EFFECT OF HUMAN ERYTHROPOIETIN DERIVED FROM RECOMBINANT DNA ON THE ANAEMIA OF PATIENTS MAINTAINED BY CHRONIC HAEMODIALYSISThe Lancet, 1986
- Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiencyKidney International, 1984